/** blogpostTitle: "Camlin Fine Sciences Q1 FY27: Record Revenue, But Margin Pressure Takes Center Stage" */

Camlin Fine Sciences Q1 FY27: Record Revenue, But Margin Pressure Takes Center Stage

Camlin Fine Sciences opened FY27 with its highest ever quarterly revenue, but the quarter also showed how quickly input inflation and logistics friction can compress profitability in a global specialty ingredients business. For Q1 FY27, the company reported consolidated revenue from continuing operations of INR 5,198.8 million (INR 519.88 crore), up 27.5 percent year on year. Adjusted EBITDA, however, declined to INR 176.4 million (INR 17.64 crore), translating to a 3.4 percent margin. Profit after tax from continuing operations was a loss of INR 318.0 million (INR 31.80 crore).

Management framed the quarter as a revenue-led performance with margin headwinds. Higher raw material prices, limited ability to pass increases through immediately, and a tougher freight environment weighed on gross margin and elongated the working capital cycle. The company also recorded an exceptional item of INR 111.1 million (INR 11.11 crore), related to a shortfall in settlement of an insurance claim for the fire at its Brazil unit.

A quarter of strong growth across segments, but uneven profitability

The company has introduced segment reporting and said it has reorganised the way it evaluates the business into three main verticals: Specialty Ingredients, Aroma, and Performance Chemicals. The new view helps explain the Q1 pattern: growth was broad-based, but profitability was held back by cost pressures and, in the case of Aroma, low capacity absorption during a cautious ramp-up.

Specialty Ingredients remained the growth engine. In Q1 FY27, straights revenue rose to INR 927 million (INR 92.7 crore), up 41 percent year on year. Value-added blends revenue reached INR 3,086 million (INR 308.6 crore), up 35 percent. Combined Specialty Ingredients revenue was INR 4,013 million (INR 401.3 crore). Segment EBITDA margin was 6.35 percent, lower than what management implied would be possible in a more normal raw material and logistics environment.

Aroma Ingredients also grew sharply in revenue terms. Q1 FY27 revenue was INR 774 million (INR 77.4 crore), up 37 percent year on year. Yet the segment delivered negative adjusted EBITDA margin of minus 4.37 percent. On the call, management attributed this to under-absorption of fixed costs during an ethyl vanillin campaign that was ramped up carefully to ensure quality and customer approvals.

Performance Chemicals and Others, which includes intersegment transactions, reported revenue of INR 1,749 million (INR 174.9 crore) and an EBITDA margin of minus 2.54 percent. Management highlighted that the diphenol plant remains shut for economic reasons, with intermediates being sourced from China because prices are competitive versus domestic production.

Financial summary (continuing operations, consolidated)

What drove the margin drop: raw materials, pass-through lag, and working capital stretch

The company’s presentation pointed to higher raw material prices and limited pass-through as key reasons gross margin fell to 41.2 percent versus 48.5 percent in Q4 FY26. Management also noted liquidity constraints and financing costs in trade flows as additional pressure points. On the call, management described a one-quarter lag in passing raw material increases to customers, which became visible in Q1.

Logistics also played a role. Management highlighted higher logistics cost and longer delivery times, which can matter disproportionately for businesses that operate across multiple geographies. The working capital cycle was described as elongated, with management stating a consolidated working capital cycle of around 100 days. Longer shipping routes and slower recoveries from customers due to a broader slowdown were cited as contributors.

The Brazil fire had an accounting impact as well. Management said the insurance claim was around INR 400 million and the company accepted a haircut to settle for cash, resulting in an exceptional item recognised in the quarter.

Vanillin execution is the operational swing factor

Aroma was the segment investors questioned most. Management’s answer was direct: utilization and campaign execution are central. During Q1, the company ran an ethyl vanillin campaign and said ramp-up was intentionally slow to meet stringent quality expectations. It said about 95 percent of customers have approved ethyl vanillin, and it expects to complete the campaign in mid-August before switching to methyl vanillin.

For Q2 FY27, management indicated expected sales volume of 500 to 600 metric tons for Aroma and guided that the segment should turn positive EBITDA. It also said Q3 could be the quarter when overall company margins return to double digits, supported by a methyl vanillin run and better utilization.

Management also revised its FY27 vanillin production estimate to around 3,000 tons, down from an earlier range of 3,600 to 4,000 tons, due to a slower-than-planned ramp-up and downtime associated with switching campaigns.

Strategy update: Blends scaling, acquisitions, and decisions on diphenol

The company reiterated that blends remains central to its model, describing it as knowledge-led rather than purely chemical manufacturing. In the presentation, it highlighted the role of clean label products, functional ingredients, and new technologies.

Two acquisitions are positioned as extensions of this strategy. Vitafor is described as a Belgium-based platform near the Port of Antwerp, intended to strengthen European and African reach in animal feed ingredients and nutritional additives. Vinpai is positioned as an ingredient-tech company focused on natural and functional systems, which the company said deepens food-ingredient capabilities and supports cross-technology innovation.

On Performance Chemicals, management acknowledged the diphenol shutdown and said it is evaluating alternatives for the asset. It expects to take a decision by Q3 FY27 on whether to repurpose the plant for other products or resume diphenol production if input economics improve.

Guidance and what to watch next

Management maintained confidence on demand and the revenue line, citing secure business lines and strong visibility. It discussed FY27 top line in the range of INR 2,200 to 2,300 crore and said the key variable is margins. EBITDA margin guidance was discussed at about 10 to 12 percent (also stated as 10 to 11 percent). For FY28, management indicated that 12 to 14 percent EBITDA margin could be achievable.

The near-term checklist is clear from the commentary. First, Specialty Ingredients needs to recover margin through improved pass-through and stabilisation of newer operations. Second, Aroma must move from a utilization-driven loss to a steady positive contributor as methyl vanillin campaigns scale. Third, Performance Chemicals needs to reduce the drag from the diphenol shutdown and improve profitability as cost structures adjust.

Camlin Fine Sciences ended Q1 FY27 with strong revenue momentum but with profitability under visible pressure. Management’s confidence is tied to improved capacity utilization, partial price pass-through in blends, and a better second half as fixed costs stay largely stable and volumes rise. The next two quarters, especially Q3 which management pointed to as the normalization point, will be the key test of that recovery narrative.